tbuckley/cabot-search huggingface dataset:
Epidemiology of National Collegiate Athletic Association men's and women's tennis injuries, 2009/2010–2014/2015
Authors: Robert C Lynall, Zachary Y Kerr, Aristarque Djoko, Babette M Pluim, Brian Hainline, Thomas P Dompier
Journal: British Journal of Sports Medicine (2015)

Background This study describes the epidemiology of men's and women's tennis injuries reported by the National Collegiate Athletic Association (NCAA) Injury Surveillance Program (ISP) during the 2009/2010–2014/2015 academic years. Methods Injuries and athlete-exposure (AE) data originated from 19 varsity men's programmes (38 team-seasons); women's tennis data originated from 25 varsity programmes (52 team-seasons). Injury rates, injury rate ratios (IRRs) and injury proportions ratios (IPRs) were reported with 95% CIs. Results The ISP captured 181 and 227 injuries for men's and women's tennis, respectively, for injury rates of 4.89 and 4.88/1000 AE for men and women, respectively. There were 32.2% and 63.9% reductions in men's and women's tennis practice injury rates between 2009/2010–2011/2012 and 2012/2013–2014/2015, but no reductions in competition injury rates. Competition injury rates were higher than practice injury rates in men's (IRR=2.32; 95% CI 1.72 to 3.13) and women's tennis (IRR=1.77; 95% CI 1.35 to 2.33). Most injuries in men's and women's tennis occurred to the lower extremities (47.0% and 52.4%, respectively), compared with the trunk (16.6% and 17.6%, respectively) and upper extremities (23.8 and 23.8, respectively). Conclusions Injury rates in NCAA men's and women's tennis were similar overall. Practice injury rates in men's and women's tennis have declined, although competition rates have not changed. These findings may help inform injury prevention programmes in the future.
Treatment of advanced neuroendocrine tumors: Results of the UKINETS and NCRI randomized phase II NET01 trial.
Authors: Philippa Corrie, Martyn Caplin, Nicholas Reed, Wendi Qian, Si-houy Lao-Sirieix, Richard Hardy, Graham Armstrong, Juan W. Valle, Denis Charles Talbot, David Cunningham, Tu Vinh Luong, Ashley Shaw, Tim Meyer
Journal: Journal of Clinical Oncology (2012)

4121 Background: Chemotherapy is widely used for advanced, unresectable neuroendocine tumours (NETs) but only four randomised trials are published. The first combined streptozocin (strep) and 5fluorouracil (5FU), reporting 63% response rate (RR), but subsequent retrospective studies had lower RRs (6-45%). Cisplatin has been combined with strep+5FU in a retrospective study with promising activity in NETs and capecitabine (cap) has been effectively substituted for 5FU in many tumours. The NET01 trial was designed to investigate whether cap+strep ± cisplatin warrant further evaluation. Methods: Patients (pts) with histologically confirmed, unresectable, advanced and/or metastatic NETs of foregut, pancreatic or unknown primary site were randomised (ratio 1:1) to 6 cycles of 3-weekly cap 625 mg/m 2 po bd daily (D1-21), strep 1.0g/m 2 IV (D1), with cisplatin 70mg/m 2 IV(D1) (Cap-cist) or without (Cap-strep). The primary outcome measure was RR using RECIST criteria (v 1.0). 84 pts were required to test a RR of &lt;40% vs &gt;60% with a significance level of 5% and 80% power in each arm. Central pathology review was performed; retrospective central radiology review was undertaken on 10% of randomly selected cases. Results: 86 pts (58% male, median age 59 years) were randomised (44 Cap-strep, 42 Cap-cist) with primary site – foregut 20%, pancreatic 48% and unknown 33%. The grade was low 8 (11%), intermediate 47 (67%) and high 15 (21%). Baseline characteristics were balanced between the 2 arms. 60% Cap-strep pts received ≥6 cycles compared with 33% Cap-cist pts. 17 Cap-strep and 26 Cap-cist pts experienced grade ≥3 toxicities. Outcome results are summarised in the table. Ki67, mitotic index or primary site of origin did not appear to predict for response. Conclusions: The novel Cap-strep ± cisplatin regimens were associated with overall disease control and survival durations consistent with published studies. Cap-strep was better tolerated than Cap-cist. Further prospective randomised studies are required to determine optimal NET chemotherapy. [Table: see text]
A phase II study of IV gemcitabine (G) and oral capecitabine (C) in patients (pts) with advanced renal cell cancer (RCC): Results of Southwest Oncology Group study 0312
Authors: P. J. Van Veldhuizen, M. Hussey, P. N. Lara, P. H. Gumerlock, J. Clark, M. K. Lange, E. D. Crawford
Journal: Journal of Clinical Oncology (2007)

15562 Background: Previous reports have suggested benefit of GC in a modest number of patients with RCC but with concerns regarding toxicity. We subsequently evaluated an adjusted dose regimen in pts with advanced unresectable or metastatic RCC. Methods: Pts who had not received prior chemotherapy where treated with G at 900mg/m2 days 1,8,15 and C at 625mg/m2 BID day 1- 21 of a 28 day cycle. Pts must have had adequate performance status, organ function and may have received prior immunotherapy. The primary endpoint was probability of response, confirmed and unconfirmed complete (CR) and partial responses (PR). A one-stage design for accrual was used and regimen would not be considered of interest if the true probability of response was &lt;=5%. Results: 43 patients were enrolled of which 1 was ineligible and 2 were not analyzable. Median follow-up was 11.2 months (range: 1.3 to 18.5). One confirmed complete response (CR) and three unconfirmed partial responses (PR) were observed, for an overall response probability of 10% (95% CI: 3% to 24%). Four of the eligible patients had inadequate disease assessment and were assumed to be non-responders. 19 pts (48%) had stable disease (SD). The 6-month probability of being free from treatment failure was 20% (95% CI: 8% to 32%). The probability of survival at 6 months was estimated to be 75% (95% CI: 62% to 88%). Median survival was estimated to be 13 months (lower limit of 95% CI is 7 months, upper limit not estimable). One patient each experienced Grade 4 neutropenia, fatigue, thrombocytopenia and hemolysis/renal failure. Most common Grade 3 toxicities were neutropenia (12 pts), fatigue (5 pts), and leucopenia (4 pts). Conclusions: GC at this dose and schedule benefits a small percentage of pts with RCC with an acceptable toxicity profile. Given the RR and SD, GC may serve as a base regimen for combination therapy with targeted agents. No significant financial relationships to disclose.
Fludarabine/rituximab (FR) followed by alemtuzumab as first-line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): A Minnie Pearl Cancer Research Network phase II trial
Authors: W. H. Liggett, J. D. Hainsworth, D. R. Spigel, A. A. Meluch, E. L. Raefsky, S. Kennedy, M. Thomas, M. Grimaldi, R. A. Saez, F. A. Greco
Journal: Journal of Clinical Oncology (2005)

6556 Background: The addition of rituximab to fludarabine-based chemotherapy has improved the molecular CR rate and extended progression-free survival as first-line treatment for CLL/SLL. Alemtuzumab improves the CR rate in patients (pts) with residual disease following first-line FR combinations. In this multicenter, community-based phase II trial, we evaluate the efficacy and toxicity of FR followed by short course alemtuzumab. Methods: Eligibility criteria: untreated CLL/SLL requiring treatment; stages II-IV; ECOG PS 0–2; platelet count > 50,000/μL; adequate liver and kidney function; informed consent. All pts received fludarabine 25mg/m2 IV days 1–4, repeated every 28 days for 4 courses, and rituximab 375mg/m2 on weeks 1, 2, 3, 4, 5, 9, and 13. 4 weeks after completion of FR, responding pts received alemtuzumab 30mg 3 times weekly for 4 weeks. Final restaging occurred 4 weeks after completion of alemtuzumab. Results: 37 pts enrolled between 2/02 and 11/04: median age 58 years; male/female, 59%/41%; CLL/SLL, 73%/27%; WBC > 50,000/μL, 43% of pts. 5 pts are still receiving treatment. Of the remaining 32 pts, 29 completed FR, and 21 completed alemtuzumab treatment as planned. 3 pts were withdrawn during FR (myelosuppression, 1; MI 1; facial swelling, 1) and 7 during alemtuzumab (infusion reactions, 4; infection, 2; diarrhea, 1). 24 of 29 evaluable pts (83%) had objective response (CR 10, PR 14). After median follow-up of 17 months, actuarial 2-year PFS and OS are 79% and 89%, respectively. Grade 3/4 toxicity during FR: neutropenia, 26%; thrombocytopenia, 6%; infusion reactions, 6%; neutropenia/fever, 8%. Grade 3/4 alemtuzumab-related toxicity: infusion reactions, 38%; opportunistic infections, 27% (fatal in 2 pts); neutropenia, 14%; neutropenia/fever, 7%; thrombocytopenia, 7%. Conclusions: FR followed by alemtuzumab is highly active, moderately toxic first-line treatment for CLL/SLL. Opportunistic infections are common but manageable in most pts. This type of intensive first-line treatment merits additional evaluation in good performance status pts with CLL/SLL. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors.
Authors: P. A. Zucali, M. Simonelli, F. De Vincenzo, E. Lorenzi, L. Rimassa, L. Balzarini, V. Quagliuolo, A. Lambiase, C. Bordignon, A. Santoro
Journal: Journal of Clinical Oncology (2011)

2522 Background: NGR-hTNF consists of tumor necrosis factor fused with the peptide NGR, which selectively binds to CD13 overexpressed on tumor blood vessels. Maximum tolerated dose (MTD) of NGR-hTNF was formerly established at 45 µg/m2 as 1-h infusion every 3 weeks (q3w), with dose limiting toxicity (DLT) being grade 3 acute infusion reactions. We aimed at testing further dose escalations by longer infusion (2-h) and mild premedication (paracetamol). Methods: 4 patients (pts) were enrolled at each of 8 dose levels (DLs: 60-250 μg/m² q3w). Any related grade 3-4 toxicity was defined DLT. Pharmacokinetics and pharmacodynamics (soluble TNF receptors: sR1-sR2) were tested in 33 pts (DLs: 60-250). To assess the effects on tumor vascularity, volume transfer coefficient (Ktrans) and initial area under gadolinium concentration (IAUGC) were evaluated 24-h before and 2-h after dosing in 21 pts (DLs: 80-225) by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Results: Overall, 34 pts (median age: 61 years; PS 0/1: 17/17) received 81 cycles (range 1-6). Prior lines ranged from 1 to 7 (median 3). No DLT occurred and MTD has not yet been reached. Related toxicities were grade 1 chills in 18 pts (53%) over 34 cycles (42%). Nine pts (26%) had grade 2 toxicities. Cmax and AUC increased with dose (p=.0006 and p=.001, respectively). Levels of sR2 peaked higher than those of sR1 (7.9 v 3.6 ng/mL; p<.0001). Changes in sRs however did not differ across DLs (p=.49 for sR1 and p=.43 for sR2), suggesting a plateau in shedding kinetics. By DCE-MRI, pre- and post-first cycle values were 0.25 and 0.19 min-1 for Ktrans and 16.6 and 12.1 mM/L/sec for IAUGC, respectively. Dose-unrelated reductions in tumor vascularity were noted in 15 pts (71%). In these pts, Ktrans significantly decreased from 0.19 to 0.07 min-1 (p=.0001) with median change of -62% (range -24 to -91), whereas IAUGC declined from 12.7 to 7.9 mM/L/sec (p=.0001) with median reduction of -42% (-3 to -76). These decreases correlated inversely with high baseline values of Ktrans (r= -0.93, p=.0001) and IAUGC (r= -0.60, p=.02). Additional dose escalations are ongoing. Conclusions: NGR-hTNF can be safely escalated at doses higher than MTD and induces low shedding of receptors and early antivascular effects.
Standard Peritoneal Permeability Analysis in Children
Authors: ANTONIA H. M. BOUTS, JEAN-CLAUDE DAVIN, JAAP W. GROOTHOFF, SJOERD PLOOS VAN AMSTEL, MACHTELD M. ZWEERS, RAYMOND T. KREDIET
Journal: Journal of the American Society of Nephrology (2000)

Abstract. Peritoneal transport characteristics in children on peritoneal dialysis (PD) has been reported to be different compared to adults. However, various test methods can influence this difference. Thirty-one standard peritoneal permeability analyses (SPA) were performed in 18 PD children with a median (range) age of 9.8 yr (2 to 19) and a median duration of PD of 2.6 yr (0.19 to 6.8). The median mass transfer area coefficient (MTAC) for creatinine was 9.6 ml/min per 1.73 m 2 (4.4 to 18.0), and for urea 17.3 ml/min per 1.73 m 2 (12.2 to 22.8). The median dialysate to plasma creatinine ratio ( D/P Cr ) was 0.69 (0.44 to 0.92), the glucose absorption 59% (23 to 75), and the D/D 0 for glucose 0.38 (0.23 to 0.62). The median clearance of β 2 -microglobulin was 923 μl/min per 1.73 m 2 (366 to 1828), of albumin 103 μl/min per 1.73 m 2 (55 to 211), of IgG 48 μl/min per 1.73 m 2 (20 to 105), and of α 2 -macroglobulin 12 μl/min per 1.73 m 2 (5 to 49). No correlation was found between these results and age or PD time. The restriction coefficient for macromolecules indeed increased with duration of PD treatment ( r = 0.38, P = 0.03). The median transcapillary ultrafiltration rate was 1.2 ml/min per 1.73 m 2 (-0.01 to 2.8), the net ultrafiltration rate 0.2 ml/min per 1.73 m 2 (-1.97 to 1.82), and the effective lymphatic absorption rate 1.04 ml/min per 1.73 m 2 (-0.06 to 2.91). When corrected for body surface area, no differences were found in peritoneal fluid and solute transport characteristics between children and adults. No effect of time on PD on the transport parameters was found in a cross-sectional analysis, except for an increase of the restriction coefficient to macromolecules. This finding is similar to observations in adults. Therefore, the present study showed no evidence for the common belief that the peritoneal membrane in children is different from that in adult patients.
Estimation of minimum clinically important difference in EQ-VAS score after pulmonary rehabilitation in COPD patients
Authors: Sabrina Della Patrona, Andrea Zanini, Marina Aiello, Daniela Adamo, Silvia Casale, Francesca Cherubino, Eleonora Raimondi, Elisabetta Zampogna, Alfredo Chetta, Antonio Spanevello
Journal: European Respiratory Journal (2014)

Introduction: The effect of pulmonary rehabilitation (PR) on EuroQol (EQ-5D) in COPD has been poorly investigated.

In addition,conflicting results have been so far reported about the VAS (Visual Analogic Scale) component of EQ-5D (EQ-VAS).

Aim: To evaluate the responsiveness of EQ-VAS to PR and its relationship with clinical and functional parametersin COPD patients.To define minimum clinically important difference (MCID) estimate for the EQ-VAS after PR.

Methods:468 stable moderate-to-severe COPD inpatients,allocated to a three-weeks PR program, were retrospectively evaluated.EQ-VAS was assessed before and after PR and its relationship with baseline pulmonary function and with changes in 6MWT and dyspnea (BDI/TDI) after PRwere evaluated.Using an anchor-based approach and receiver operating characteristic (ROC)curves,the EQ-VAS change cutoff that identified patients achieving the known MCID for TDI with PR was identified.

Results: 439 patients (94%, mean FEV1 55.3% predicted) were able to complete pre- and post-PR VAS score. After PR, EQ-VAS increased from 58±17 to 72±15 (ΔEQ-VAS 14±12, p<0.001 ). ΔEQ-VAS was negatively related to baseline FEV1 (r=-032, p<0.001) and positively to TDI (r=0.50, p<0.001) and 6MWD (r=0.46, p<0.001) changes. ROC curves identified an EQ-VAS change cutoff of 8 points, as the best discriminating value to identify the MCID for TDI (area under curve: 0.845,p<0.001).

Conclusions: Our study shows that in stable moderate-to-severe COPD inpatients, EQ-VAS is a valid and reliable tool to assess theresponsiveness to PR, with an estimated MCIDof 8 points. The EQ-VAS can be a practical alternative to more time-consuming measures of HrQoL.
Carcinogenic Effect of Carbazole in the Liver of (C57BL/6N × C3H/HeN)F&lt;sub&gt;1&lt;/sub&gt; Mice&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: H Tsuda, A Hagiwara, M Shibata, M Ohshima, N Ito
Journal: JNCI Journal of the National Cancer Institute (1982)

The carcinogenic effect of carbazole (9H-carbazole) in (C57BL/6N X C3H/HeN)F1 (B6C3F1) mice was examined. Groups of 50 mice of both sexes were given a basal diet containing 0.6, 0.3, or 0.15% carbazole for 96 weeks and were then placed on an unsupplemented basal diet until they were killed at week 104. Mice surviving longer than 52 weeks were included in effective numbers. Significant increases in the induction of neoplastic lesions were found in the livers and forestomachs of mice given carbazole as compared to the control groups. The lesions in the livers were classified into two types, neoplastic nodules or hepatocellular carcinomas. The incidences of both types of lesions were almost 100% in mice treated with carbazole, and both types of lesions were significantly increased in all mice except the males given 0.6% carbazole in their diet. The incidences of hepatocellular carcinomas were in general higher than those of neoplastic nodules. Though not statistically significant, increased incidences of pulmonary metastases were found in the groups given carbazole. Significantly increased incidences of neoplastic lesions and papillomas in the forestomach in all groups of female and male mice were also noted in the mice fed 0.6% carbazole. Squamous cell carcinoma induction was significantly different in male mice given 0.6% carbazole as compared to controls. These results indicate that carbazole is carcinogenic to the liver and forestomach in B6C3F1 mice and suggest that carbazole may be an environmental carcinogen relevant to cancer risk in humans.
Synergistic cytotoxic/apoptotic effects of AT-101, a phytochemical with BH3-mimetic property, in combination with paclitaxel in human breast cancer cells.
Authors: S. B. Karaca, U. Muslu, B. Cakar, A. Kisim, H. Atmaca, D. Unuvar Purcu, S. Uzunoglu, R. Uslu
Journal: Journal of Clinical Oncology (2010)

e21082
Abstract 057: Increased Incidence of Ischemic Stroke in HIV-Infected Women in a Clinical Care Cohort
Authors: Felicia C Chow, Susan Regan, Steven Feske, James B Meigs, Steven K Grinspoon, Virginia A Triant
Journal: Circulation (2012)

Introduction: Coronary heart disease rates are increased among HIV-infected patients compared to control groups, with a relatively greater increase in women compared to men. Whether a similar pattern with respect to gender is true for ischemic stroke is not known. We assessed the hypothesis that the adjusted hazard ratio for ischemic stroke given HIV infection is greater among women compared to men. Methods: The study was conducted using data from an HIV observational clinical care cohort at a large Boston-based health care system. A control cohort of non-HIV-infected patients was matched in a 10:1 ratio to the HIV cohort based on age, gender, and race. The observation period was between 1996 and 2009, with right censoring at the initial stroke event or last encounter if prior to 2009. Ischemic stroke events were identified by pre-specified and validated ICD-9-CM codes. Gender-specific stroke incidence rates were calculated. To assess the association of HIV and ischemic stroke within each gender, Cox proportional hazard modeling was employed. Results: The cohorts consisted of 4,308 HIV-infected patients (31% women) and 32,423 non-HIV-infected patients (35% women). Among women, ischemic stroke event rates were 5.02 per 1000 person years (PY) in HIV-infected versus 2.31 per 1000 PY in non-HIV-infected patients (40 events in HIV and 177 events in non-HIV) with an unadjusted hazard ratio (HR) of 2.16 (95% confidence interval [CI] 1.53–3.04, P &lt;0.001). In contrast, among men ischemic stroke rates were 5.38 per 1000 PY in HIV-infected versus 4.59 per 1000 PY in non-HIV-infected patients (92 events in HIV and 605 events in non-HIV patients) with an unadjusted HR of 1.18 (95% CI 0.95–1.47, P =0.14). Comparing HIV-infected to non-HIV-infected patients, incidence rates were significantly increased among women in the 18–29, 30–39, and 40–49 age groups and among men in the 30–39 age group. In a gender-stratified, multivariate regression model adjusting for age, race, hypertension, diabetes, dyslipidemia, smoking, structural heart disease, atrial fibrillation, aspirin use, and warfarin use, the adjusted HR for stroke associated with HIV infection was 1.76 (95% CI 1.24–2.52, P =0.002) among women compared with 1.05 (95% CI 0.84–1.32, P =0.639) among men. Conclusions: Ischemic stroke incidence rates were significantly increased in HIV-infected patients compared to non-HIV-infected patients among young women (&lt; 50) and a subset of young men. HIV infection remained independently associated with stroke among women after adjusting for demographic and traditional stroke risk factors. While further studies are merited investigating causality and potential mechanisms for stroke among HIV-infected women, this group may represent a uniquely at-risk population for accelerated cerebrovascular aging.
Drug resistance in clinical practice: patterns of treatment failure in advanced breast and ovarian cancer.
Authors: P R Harnett, F Kirsten, M H Tattersall
Journal: Journal of Clinical Oncology (1986)

We have analyzed the patterns of disease progression in patients with advanced breast and ovarian cancer receiving systemic therapy. Approximately 50% of patients developed progressive disease in a new, rather than a previously documented, disease site. Even when disease progressed in a previously involved disease site, in only half the cases was this identified as the bulk disease site before commencing treatment. The CNS was rarely a new site of disease progression in our patients, a finding that contrasts with a report that identified the CNS as the predominant new disease site in advanced breast cancer patients relapsing following a complete response. Progression of disease on second line treatment commonly occurred at sites of known disease. A number of factors influencing the pattern of disease progression have been examined. Disease progression on endocrine therapy tended to be more common in a previously involved disease site than in patients receiving cytotoxic therapy. There was a trend for patients who progressed within 6 months of chemotherapy to do so in an old site, whereas new disease sites predominated among those progressing later. Strategies for overcoming the causes of treatment failure should take account of the patterns of disease progression. Our results question the wisdom of always ceasing existing therapy when progressive disease is first documented.
Nucleotide-Induced Inhibition of Surface Sialyl Transferase Activity on Cultured Burkitt's Lymphoma Cells23
Authors: Lary J. Kilton, Richard D. Maca
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Nucleotide-Induced Inhibition of Surface Sialyl Transferase Activity on Cultured Burkitt's Lymphoma Cells Get access Lary J. Kilton, Lary J. Kilton Search for other works by this author on: Oxford Academic PubMed Google Scholar Richard D. Maca Richard D. Maca 5 5Address reprint requests to Dr. Maca. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 5, May 1977, Pages 1479–1481, https://doi.org/10.1093/jnci/58.5.1479 Published: 01 May 1977 Article history Received: 28 June 1976 Accepted: 14 October 1976 Published: 01 May 1977